ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintTitle ChevronIcon Twitter
Markets

JD.com's online health care subsidiary files for IPO

Fresh funds earmarked by JD Health for R&D

JD Retail head Xu Lei, center, marks the listing of JD.com on the Hong Kong Stock Exchange at JD.com headquarters in Beijing on June 18.   © AP

HONG KONG -- JD Health, the health care subsidiary of Chinese e-commerce giant JD.com, filed for an initial public offering to the Hong Kong Stock Exchange by Monday in a bid to raise $1.8 billion to $2.8 billion within the year.

JD Health operates the largest pharmaceutical retail website in China, and plans to use the fresh funds for research and development.

JD.com carried out a secondary listing in Hong Kong in June. The parent launched its health care business in 2014 and began online diagnosis services in 2017. It plans to maintain a majority stake in JD Health after the IPO.

In China, lifestyle-related diseases are increasing, boosting demand in the health care sector. The coronavirus has accelerated this demand, in addition to driving people to online medical services.

According to documents filed by JD Health, revenue jumped 76% to hit 8.7 billion yuan ($1.2 billion) year on year in the six months through June.

Chinese tech giants have sought to harness health-related businesses to drive growth, rolling out a wide range of services like online consultations, hospital reservations and pharmaceutical sales.

Ping An Good Doctor, a unit of Ping An Insurance Group, and Alibaba's health care arm Alibaba Health Information Technology have both gone public in Hong Kong.

WeDoctor, an online medical services provider backed by Tencent Holdings, is also getting ready for a share float in Hong Kong.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends October 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more